$0.02 EPS Expected for GoDaddy Inc. (GDDY); Aveo Pharmaceuticals Has 2.81 Sentiment

April 17, 2018 - By Peter Erickson

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Logo

Analysts expect GoDaddy Inc. (NYSE:GDDY) to report $0.02 EPS on May, 8 after the close.They anticipate $0.01 EPS change or 100.00% from last quarter’s $0.01 EPS. GDDY’s profit would be $3.36M giving it 799.13 P/E if the $0.02 EPS is correct. After having $0.11 EPS previously, GoDaddy Inc.’s analysts see -81.82% EPS growth. The stock increased 2.90% or $1.8 during the last trading session, reaching $63.93. About 782,561 shares traded. GoDaddy Inc. (NYSE:GDDY) has risen 64.62% since April 17, 2017 and is uptrending. It has outperformed by 53.07% the S&P500.

Aveo Pharmaceuticals Inc (AVEO) investors sentiment increased to 2.81 in Q4 2017. It’s up 1.49, from 1.32 in 2017Q3. The ratio is more positive, as 45 investment managers opened new and increased positions, while 16 sold and reduced their stakes in Aveo Pharmaceuticals Inc. The investment managers in our database now own: 59.55 million shares, down from 59.90 million shares in 2017Q3. Also, the number of investment managers holding Aveo Pharmaceuticals Inc in top ten positions decreased from 3 to 1 for a decrease of 2. Sold All: 4 Reduced: 12 Increased: 19 New Position: 26.

GoDaddy Inc. designs and develops cloud technology products for small businesses, Web design professionals, and individuals in the United States and internationally. The company has market cap of $10.74 billion. It provides domain name registration product that enables to engage clients at the initial stage of establishing a digital identity; hosting and presence products, such as shared Website hosting, Website hosting on virtual dedicated servers and dedicated servers, managed hosting, and security. It has a 80.92 P/E ratio. The firm also offers Website builder, an online tool that enables clients to build Websites; online store product that allows clients to create their own standalone Website with an integrated online store optimized for mobile shopping; and search engine visibility product that helps clients get their Websites found on search sites through search engine optimization.

Among 25 analysts covering GoDaddy Inc (NYSE:GDDY), 17 have Buy rating, 1 Sell and 7 Hold. Therefore 68% are positive. GoDaddy Inc had 71 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Monday, June 26 by Cantor Fitzgerald. The stock has “Buy” rating by William Blair on Monday, April 2. The stock has “Buy” rating by Deutsche Bank on Monday, August 14. The stock of GoDaddy Inc. (NYSE:GDDY) has “Outperform” rating given on Wednesday, August 9 by Raymond James. The rating was maintained by Oppenheimer with “Buy” on Thursday, April 5. The rating was maintained by Jefferies with “Buy” on Tuesday, November 7. The rating was maintained by Oppenheimer with “Outperform” on Thursday, August 6. The rating was maintained by Deutsche Bank on Thursday, November 5 with “Buy”. JMP Securities maintained it with “Market Outperform” rating and $68 target in Friday, February 23 report. As per Tuesday, April 5, the company rating was initiated by Singular Research.

Analysts await AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report earnings on May, 3. They expect $-0.06 EPS, up 50.00% or $0.06 from last year’s $-0.12 per share. After $-0.08 actual EPS reported by AVEO Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $429.31 million. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

The stock decreased 0.54% or $0.015 during the last trading session, reaching $2.785. About 652,543 shares traded. AVEO Pharmaceuticals, Inc. (AVEO) has risen 351.31% since April 17, 2017 and is uptrending. It has outperformed by 339.76% the S&P500.

Deer Vi & Co. Llc holds 100% of its portfolio in AVEO Pharmaceuticals, Inc. for 675,242 shares. Nea Management Company Llc owns 16.36 million shares or 1.89% of their US portfolio. Moreover, Emory University has 1.44% invested in the company for 602,883 shares. The New York-based New Leaf Venture Partners L.L.C. has invested 1.26% in the stock. Ra Capital Management Llc, a Massachusetts-based fund reported 5.06 million shares.

Since January 1, 0001, it had 10 buys, and 0 selling transactions for $21.15 million activity.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Peter Erickson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: